{
    "clinical_study": {
        "@rank": "18358", 
        "arm_group": [
            {
                "arm_group_label": "Ketamine Intravenous (IV)", 
                "arm_group_type": "Experimental", 
                "description": "Patients will receive a single IV dose of ketamine given as a continuous infusion."
            }, 
            {
                "arm_group_label": "Placebo Intravenous (IV)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients will receive a single IV dose of placebo given as a continuous infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate if somatosensory evoked potentials (SEPs) and motor evoked potentials (MEPs)\n      obtained with electroencephalography (EEG) and electromyography (EMG) can be used to detect\n      changes in cortical plasticity in responders to a single IV infusion of ketamine as compared\n      to non-responders."
        }, 
        "brief_title": "A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be conducted in patients with Major Depressive Disorder (MDD) and divided\n      into 2 sequential cohorts. Cohort 1 will be conducted in 12 patients at a single center. For\n      each patient, there will be up to 4 sequential phases: a screening phase of up to 6 weeks,\n      an open-label treatment phase of up to 4 weeks, an optional open-label treatment phase of up\n      to 1 week, and a follow-up phase of up to 1 week (if applicable). Cohort 2 will be conducted\n      in 20 patients and will be a multicenter, double-blind (neither physician nor patient knows\n      the treatment that the patient receives), randomized (the study drug is assigned by chance),\n      placebo-controlled (an inactive substance that is compared with a drug to test whether the\n      drug has a real effect in a clinical trial) design. For each patient, there will be up to 4\n      sequential phases: a screening phase of up to 6 weeks, a double-blind treatment phase of up\n      to 4 weeks, an optional open-label treatment phase of up to 1 week, and a follow-up phase of\n      up to 1 week (if applicable). The total study duration for each patient will be maximally\n      about 12 weeks. Participant safety will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be medically stable\n\n          -  Patient must meet Diagnostic and Statistical Manual of Mental Disorders - Fourth\n             Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder (MDD), without\n             psychotic features, based upon clinical assessment and confirmed by the Mini\n             International Psychiatric Interview (MINI)\n\n          -  Patient must have had an inadequate response to at least 2 antidepressants, one of\n             which is in the current episode of depression\n\n          -  Patient must have an Inventory of Depressive Symptomatology 30-item Clinician-rated\n             (IDS-C30) total score \u2265 34 at Screening and Day -1\n\n          -  Women must be postmenopausal, surgically sterile, or, if heterosexually active,\n             practicing a highly effective method of birth control\n\n          -  Men who are heterosexually active with a woman of childbearing potential must agree\n             to use a double barrier method of birth control and to not donate sperm during the\n             study and for 3 months after receiving the last dose of study drug\n\n        Exclusion Criteria:\n\n          -  Patient has current signs and/or symptoms of liver or renal insufficiency;\n             significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic,\n             hematologic, rheumatologic, or metabolic disturbances\n\n          -  Patient has a primary DSM-IV diagnosis of current (active) generalized anxiety\n             disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic\n             stress disorder (PTSD), anorexia nervosa, or bulimia nervosa\n\n          -  Patient has a current diagnosis of bipolar disorder, mental retardation, or cluster b\n             personality disorder (e.g., borderline personality disorders, antisocial personality\n             disorder, etc)\n\n          -  Patient has a current or prior diagnosis of a psychotic disorder or MDD with\n             psychosis\n\n          -  Patient has not responded to treatment with electroconvulsive therapy (ECT) in the\n             current episode of depression\n\n          -  Patient has suicidal ideation with intent to act, or has homicidal ideation/intent,\n             during Screening phase per Investigator's clinical judgment\n\n          -  Patient has any significant primary sleep disorder"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01957410", 
            "org_study_id": "CR102607", 
            "secondary_id": "KETIVTRD2004"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ketamine Intravenous (IV)", 
                "description": "During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.", 
                "intervention_name": "Ketamine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo Intravenous (IV)", 
                "description": "During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketamine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Major Depressive Disorder", 
            "Ketamine", 
            "Evoked potentials", 
            "Somatosensory evoked potentials", 
            "Motor evoked potentials", 
            "Cortical plasticity"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR102607"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "SEPs are the electrical signals generated by the nervous system in response to somatosensory stimuli - typically through electrical stimulation of the median nerve. SEPs are read on the skull with electroencephalography (EEG). SEPs will be carried out as described by Cornwell and colleagues (Cornwell 2012) with the exception that instead of using magnetoencephalography SEPs will be recorded using a 64-channel EEG system. Identical procedures will be employed prior to and after study drug administration.", 
                "measure": "Comparison of change from baseline to 4 hr post-dose on Day 1 in somatosensory evoked potential amplitudes (SEPs) between ketamine responders and ketamine non-responders.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 4 hours post-dose on Day 1"
            }, 
            {
                "description": "MEPs are generated when stimulation of the brain on the motor cortex (with Transcranial Magnetic Stimulation [TMS], for example) causes the spinal cord and peripheral muscles to produce neuroelectrical signals. MEPs are typically measured in the hand muscles. The Motor Evoked Response to Transcranial Magnetic Stimulation (TMS MEPs) is being evaluated in this study at baseline and regularly after study drug administration. TMS MEPs will be assessed as described by Di Lazzaro and colleagues (Di Lazzaro 2003).  A figure-of-eight coil will be held over the right motor cortex at the optimum scalp position to elicit motor responses in the contralateral first dorsal interosseus (FDI).", 
                "measure": "Comparison of change from baseline to 4 hr post-dose on Day 1 in motor evoked potential amplitudes (MEPs) between ketamine responders and ketamine non-responders.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 4 hours post-dose on Day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01957410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}